MoonLake Immunotherapeutics (MLTX) NASDAQ
$53.11 2.12 (4.16%)
Market Cap: $3.34B
As of 09/18/24 04:00 PM EDT. Market closed.
MoonLake Immunotherapeutics (MLTX)
NASDAQ
$53.11
2.12 (4.16%)
Market Cap: $3.34B
As of 09/18/24 04:00 PM EDT. Market closed.
Add to Portfolio
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake ... read more
COMPANY PROFILE
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jorge Santos da Silva
Full Time Employees
50
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jorge Santos da Silva
Full Time Employees
50
Address
Dorfstrasse 29, Zug, 6300.
PRICE CHART FOR MOONLAKE IMMUNOTHERAPEUTICS
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$51.49
Previous Close
$50.99
Days Range
$51.27 - $55.05
52 week range
$35.11 - $64.98
Volume
691,791
Avg. Volume (30 days)
326,614
Market Cap
$3.34B
Dividend Yield
-
P/E
(61.05)
Shares Outstanding
62,888,600
Open
$51.49
Previous Close
$50.99
Days Range
$51.27 - $55.05
52 week range
$35.11 - $64.98
Volume
691,791
Avg. Volume (30 days)
326,614
Market Cap
$3.34B
Dividend Yield
-
P/E
(61.05)
Shares Outstanding
62,888,600
FINANCIAL STATEMENTS FOR MOONLAKE IMMUNOTHERAPEUTICS
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR MOONLAKE IMMUNOTHERAPEUTICS
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Santos da Silva Jorge | Chief Executive Officer | Feb 29, 2024 | Sale | $55.89 | 4,740 | 264,919 | 2,982,814 | Feb 29, 2024, 07:56 PM |
| Santos da Silva Jorge | Chief Executive Officer | Feb 28, 2024 | Sale | $55.00 | 56,065 | 3,083,575 | 2,987,554 | Feb 29, 2024, 07:56 PM |
| Santos da Silva Jorge | Chief Executive Officer | Feb 27, 2024 | Sale | $55.00 | 62,810 | 3,454,550 | 3,043,619 | Feb 29, 2024, 07:56 PM |
| Reich Kristian | Chief Scientific Officer | Feb 27, 2024 | Sale | $55.00 | 29,491 | 1,622,005 | 2,957,483 | Feb 29, 2024, 07:53 PM |
| Reich Kristian | Chief Scientific Officer | Feb 28, 2024 | Sale | $55.00 | 28,090 | 1,544,950 | 41,981 | Feb 29, 2024, 07:53 PM |
| Reich Kristian | Chief Scientific Officer | Feb 28, 2024 | Sale | $55.00 | 31,910 | 1,755,050 | 2,925,573 | Feb 29, 2024, 07:53 PM |
| Reich Kristian | Chief Scientific Officer | Feb 27, 2024 | Sale | $55.00 | 29,431 | 1,618,705 | 70,071 | Feb 29, 2024, 07:53 PM |
| Santos da Silva Jorge | Chief Executive Officer | Feb 21, 2024 | Sale | $55.27 | 1,125 | 62,179 | 3,106,429 | Feb 23, 2024, 04:48 PM |
| Reich Kristian | Chief Scientific Officer | Feb 21, 2024 | Sale | $55.30 | 569 | 31,466 | 99,502 | Feb 22, 2024, 06:32 PM |
| Reich Kristian | Chief Scientific Officer | Feb 21, 2024 | Sale | $55.31 | 509 | 28,153 | 2,986,974 | Feb 22, 2024, 06:32 PM |
| Reich Kristian | Chief Scientific Officer | Feb 20, 2024 | Sale | $57.43 | 10,000 | 574,300 | 100,071 | Feb 22, 2024, 06:32 PM |
| Reich Kristian | Chief Scientific Officer | Feb 20, 2024 | Sale | $57.45 | 10,000 | 574,500 | 2,987,483 | Feb 22, 2024, 06:32 PM |
| Santos da Silva Jorge | Chief Executive Officer | Feb 16, 2024 | Sale | $60.15 | 20,000 | 1,203,000 | 3,127,554 | Feb 20, 2024, 06:36 PM |
| Santos da Silva Jorge | Chief Executive Officer | Feb 15, 2024 | Sale | $60.18 | 20,000 | 1,203,600 | 3,147,554 | Feb 20, 2024, 06:36 PM |
| Santos da Silva Jorge | Chief Executive Officer | Feb 20, 2024 | Sale | $57.44 | 20,000 | 1,148,800 | 3,107,554 | Feb 20, 2024, 06:36 PM |
| Reich Kristian | Chief Scientific Officer | Feb 14, 2024 | Sale | $62.43 | 10,000 | 624,300 | 130,071 | Feb 16, 2024, 06:02 PM |
| Reich Kristian | Chief Scientific Officer | Feb 14, 2024 | Sale | $62.42 | 10,000 | 624,200 | 3,017,483 | Feb 16, 2024, 06:02 PM |
| Reich Kristian | Chief Scientific Officer | Feb 16, 2024 | Sale | $60.15 | 10,000 | 601,500 | 110,071 | Feb 16, 2024, 06:02 PM |
| Reich Kristian | Chief Scientific Officer | Feb 16, 2024 | Sale | $60.15 | 10,000 | 601,500 | 2,997,483 | Feb 16, 2024, 06:02 PM |
| Reich Kristian | Chief Scientific Officer | Feb 15, 2024 | Sale | $60.16 | 10,000 | 601,600 | 120,071 | Feb 16, 2024, 06:02 PM |
| Reich Kristian | Chief Scientific Officer | Feb 15, 2024 | Sale | $60.17 | 10,000 | 601,700 | 3,007,483 | Feb 16, 2024, 06:02 PM |
| Bodenstedt Matthias | Chief Financial Officer | Dec 20, 2023 | Sale | $58.34 | 5,264 | 307,102 | 520,903 | Dec 21, 2023, 04:01 PM |
| Bodenstedt Matthias | Chief Financial Officer | Dec 19, 2023 | Sale | $59.22 | 94,736 | 5,610,266 | 526,167 | Dec 21, 2023, 04:01 PM |
| Chen Bihua | 10% Owner | Oct 05, 2023 | Buy | $59.90 | 58,839 | 3,524,297 | 8,494,151 | Oct 10, 2023, 04:00 PM |
| Chen Bihua | 10% Owner | Oct 03, 2023 | Buy | $57.25 | 150,487 | 8,615,682 | 8,367,498 | Oct 04, 2023, 05:52 PM |
| Chen Bihua | 10% Owner | Oct 02, 2023 | Buy | $57.37 | 74,911 | 4,297,644 | 8,217,011 | Oct 04, 2023, 05:52 PM |
| Chen Bihua | 10% Owner | Oct 04, 2023 | Buy | $57.32 | 67,814 | 3,887,017 | 8,435,312 | Oct 04, 2023, 05:52 PM |
| Chen Bihua | 10% Owner | Jun 26, 2023 | Buy | $45.63 | 450,000 | 20,535,011 | 4,127,100 | Jun 28, 2023, 06:28 PM |
| Chen Bihua | 10% Owner | Mar 21, 2023 | Buy | $21.70 | 238,511 | 5,175,999 | 3,677,100 | Mar 22, 2023, 05:07 PM |
| Chen Bihua | 10% Owner | Mar 20, 2023 | Buy | $19.71 | 588,589 | 11,598,847 | 3,438,589 | Mar 22, 2023, 05:07 PM |
| Chen Bihua | 10% Owner | Apr 05, 2022 | Buy | $10.00 | 2,850,000 | 28,500,000 | 2,850,000 | Apr 07, 2022, 06:26 PM |
| Chen Bihua | CEO and Chairman | Oct 22, 2020 | Buy | $10.00 | 430,000 | 4,300,000 | 430,000 | Oct 22, 2020, 05:10 PM |
| Helix Holdings LLC | Director | Oct 22, 2020 | Buy | $10.00 | 430,000 | 4,300,000 | 430,000 | Oct 22, 2020, 05:08 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Santos da Silva Jorge | Chief Executive Officer | 02/29/2024 | 264,919 |
| Santos da Silva Jorge | Chief Executive Officer | 02/28/2024 | 3,083,575 |
| Santos da Silva Jorge | Chief Executive Officer | 02/27/2024 | 3,454,550 |
| Reich Kristian | Chief Scientific Officer | 02/27/2024 | 1,622,005 |
| Reich Kristian | Chief Scientific Officer | 02/28/2024 | 1,544,950 |
| Reich Kristian | Chief Scientific Officer | 02/28/2024 | 1,755,050 |
| Reich Kristian | Chief Scientific Officer | 02/27/2024 | 1,618,705 |
| Santos da Silva Jorge | Chief Executive Officer | 02/21/2024 | 62,179 |
| Reich Kristian | Chief Scientific Officer | 02/21/2024 | 31,466 |
| Reich Kristian | Chief Scientific Officer | 02/21/2024 | 28,153 |
| Reich Kristian | Chief Scientific Officer | 02/20/2024 | 574,300 |
| Reich Kristian | Chief Scientific Officer | 02/20/2024 | 574,500 |
| Santos da Silva Jorge | Chief Executive Officer | 02/16/2024 | 1,203,000 |
| Santos da Silva Jorge | Chief Executive Officer | 02/15/2024 | 1,203,600 |
| Santos da Silva Jorge | Chief Executive Officer | 02/20/2024 | 1,148,800 |
| Reich Kristian | Chief Scientific Officer | 02/14/2024 | 624,300 |
| Reich Kristian | Chief Scientific Officer | 02/14/2024 | 624,200 |
| Reich Kristian | Chief Scientific Officer | 02/16/2024 | 601,500 |
| Reich Kristian | Chief Scientific Officer | 02/16/2024 | 601,500 |
| Reich Kristian | Chief Scientific Officer | 02/15/2024 | 601,600 |
| Reich Kristian | Chief Scientific Officer | 02/15/2024 | 601,700 |
| Bodenstedt Matthias | Chief Financial Officer | 12/20/2023 | 307,102 |
| Bodenstedt Matthias | Chief Financial Officer | 12/19/2023 | 5,610,266 |
| Chen Bihua | 10% Owner | 10/05/2023 | 3,524,297 |
| Chen Bihua | 10% Owner | 10/03/2023 | 8,615,682 |
| Chen Bihua | 10% Owner | 10/02/2023 | 4,297,644 |
| Chen Bihua | 10% Owner | 10/04/2023 | 3,887,017 |
| Chen Bihua | 10% Owner | 06/26/2023 | 20,535,011 |
| Chen Bihua | 10% Owner | 03/21/2023 | 5,175,999 |
| Chen Bihua | 10% Owner | 03/20/2023 | 11,598,847 |
| Chen Bihua | 10% Owner | 04/05/2022 | 28,500,000 |
| Chen Bihua | CEO and Chairman | 10/22/2020 | 4,300,000 |
| Helix Holdings LLC | Director | 10/22/2020 | 4,300,000 |
Load More Insider Transactions
FUNDS WITH A POSITION IN MOONLAKE IMMUNOTHERAPEUTICS
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,825,000 | 0.15% | -20.13% | Other |
| HOLOCENE ADVISORS, LP | 1,626,341 | 0.3% | 11.79% | Growth At A Reasonable Price |
| BALYASNY ASSET MANAGEMENT L.P. | 584,263 | 0.04% | 37.57% | Event Driven |
| BLACKROCK INC. | 392,024 | 0.00039% | -3.98% | Other |
| CANDRIAM S.C.A. | 239,000 | 0.06% | No change | Other |
| DUQUESNE FAMILY OFFICE LLC | 87,500 | 0.1% | Exited | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 58,500 | 0.00023% | 8.28% | Other |
| ALPS ADVISORS INC | 49,042 | 0.01% | 16.01% | Other |
| TUDOR INVESTMENT CORP ET AL | 27,173 | 0.00612% | -13.49% | Event Driven, Other |
| TIG ADVISORS, LLC | 8,800 (Call) | 0.03% | 72.55% | Event Driven |
| AQR CAPITAL MANAGEMENT LLC | 5,858 | 0.0005% | Exited | Other |
CHANGE IN SHARES OUTSTANDING FOR MOONLAKE IMMUNOTHERAPEUTICS
STOCK BUYBACKS FOR MOONLAKE IMMUNOTHERAPEUTICS
Period of Report: 03/31/2024
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
17.04%
2Q
09/30/2022
69.63%
6Q
06/30/2022
77.94%
7Q
BUYBACK ANNOUNCEMENT(S) FOR MOONLAKE IMMUNOTHERAPEUTICS
LOADING...